GlycoEra
Schlieren
About GlycoEra
GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases. It leverages its proprietary CustomGlycan platform to design biologics that selectively target and degrade disease-causing proteins, such as autoantibodies, without broadly suppressing the immune system. The company's lead program, GE8820, is engineered to degrade pathogenic IgG4 autoantibodies with high specificity and efficiency, addressing conditions like pemphigus, muscle-specific kinase (MuSK) myasthenia gravis, primary membranous nephropathy, and autoimmune encephalitis. This approach offers the potential for earlier intervention and improved patient outcomes compared to existing therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $179.3M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2025)
- Website: glycoera.com
- Phone: +41 44 733 8575
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/glycoera-19634 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.